Crossmark

Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovir

Crossref DOI link: https://doi.org/10.1038/s41392-025-02207-w

Published Online: 2025-04-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yifan

Wan, Yanmin https://orcid.org/0000-0001-5027-9423
Guo, Cuiyuan

Zhu, Zhaoqin

Qiu, Chao https://orcid.org/0000-0001-9401-5219
Lu, Jiasheng

Zhou, Yanan

Zheng, Jiaojiao

Dai, Fahui

Cheng, Xiaoyang

Deng, Kunlu

Wang, Wanhai

Wang, Youchun https://orcid.org/0000-0001-9769-5141
Zhang, Wenhong
License Information

Text and Data Mining valid from 2025-04-11

Version of Record valid from 2025-04-11
More Information

Article History

Received: 1 November 2024

Revised: 26 February 2025

Accepted: 13 March 2025

First Online: 11 April 2025

Competing interests

: Patent applications regarding the novel prodrugs evaluated in this study have been jointly filed by Shanghai Sci-Tech Inno Center for Infection & Immunity and Risen Pharma Tech Co., Ltd.. The authors declare no other competing interests.

Document is current

Any future updates will be listed below